tbuckley/cabot-search huggingface dataset:
A phase I, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma.
Authors: Li Zhang, Hongyun Zhao, Yuxiang Ma, Xin Zheng, Ji Jiang, Yang Zhang, Shaodong Hong, Guizhong Liu, Xiaohong She, Qingjiang Ni, Lvyu Zhu, Yi Zhu, Fangyong Felix Du, Peter Luo
Journal: Journal of Clinical Oncology (2020)

3105 Background: ADG106 is a fully human agonistic anti-CD137 monoclonal IgG4 antibody, targeting a unique epitope of CD137 with novel mechanism of actions for CD137 agonism, CD137 ligand antagonism and potent cross-linking via FcgRIIb. This phase 1 study was conducted to assess its safety, tolerability, pharmacokinetic (PK) profile, immunogenicity and preliminary efficacy. Methods: Eligible patients with age 18 to 75, ECOG ≤1, measurable lesion received intravenous infusion of ADG106 every 3 weeks for a maximum of 24 months. Accelerated titration was applied in 0.1mg/kg dose level and traditional Fibonacci 3+3 method was applied in 0.5, 1.5, 3.0, 5.0 and 10.0 mg/kg dose levels. A dose-expansion cohort will be started for dose levels that have been proved tolerable and with evidence of clinical or biological activity. Results: Data cutoff at Jan 17 2020, 15 patients [5 adenoid cystic carcinoma (ACC), 5 non-small cell lung cancer (NSCLC), 3 nasopharyngeal carcinoma, 1 malignant pleural mesothelioma and 1 follicular lymphoma] were enrolled and received treatment: 0.1mg/kg (n = 1), 0.5mg/kg (n = 3), 1.5mg/kg (n = 5), 3mg/kg (n = 3), and 5mg/kg (n = 3). Of these 15 patients, 6 with ongoing treatment, 9 discontinued (8 progression disease, 1 lack of clinical benefit). Medium treatment duration was 2 cycles (range 2-8). No dose limiting toxicities were observed. Seven (47%) patients experienced treatment-related AEs (TRAEs): rash (13%), pruritus (13%), nausea (7%), pyrexia (7%), hemoptysis (7%), mouth ulceration (7%), vomiting (7%), chest discomfort (7%), LDH increased (7%). All TRAEs were grade 1, no grade ≥3 occurred. One serious adverse event (anemia, not related) was observed. Pharmacokinetic analysis of ADG106 showed a half-life ranging from 5~10 days, with dose-dependent increase of systemic exposure. Treatment induced anti-drug antibodies were developed in 3 (20%) patients. No objective response was observed among the 14 evaluated patients. Disease control rate was 57% (8 stable disease), tumor shrinkage was observed in 3 (21%) patients (2 ACC, 1 NSCLC). Conclusions: ADG106 is safe and tolerable at doses up to 5 mg/kg in solid tumors and non-Hodgkin lymphoma. The dose expansion cohorts have started at selected doses. Clinical trial information: NCT03802955 .
Magnetic resonance imaging monitoring for osteonecrosis of the knee joints in recovered patients with severe acute respiratory syndrome after administration of glucocorticoids
Authors: 程克斌, 程晓光, 屈辉, 刘薇, 赵涛, 孙晶
Journal: BMJ (2006)

目的 评价用MRI监测经糖皮质激素治疗的严重急性呼吸综合征(SARS)患者康复后膝关节骨坏死的出现率和MRI特点.方法对99例(男22例,女77例)经糖皮质激素治疗SARS康复患者的198个膝关节进行MR检查,判断有无膝关节骨缺血坏死.结果 99例中有31例患者出现骨坏死(占31%),其中双膝多发病灶为25例,单膝发病6例;在双膝多发病例中病灶均呈对称性分布,共出现166处病灶,占发病膝关节分区的27%[166/(56×11)].病灶累及负重区与非负重区的比例为27∶ 29;病灶位于关节软骨下为84%(47/56).166处病灶累及区域:股骨内侧髁后部27处(16%),内侧髁前部14处(8%),外侧髁后部44 处(27%),外侧髁前部29处(17%),干骺端18处(11%);胫骨平台内侧髁前部3处(2%),内侧髁后部13处(8%),外侧髁前部2处(1%),外侧髁后部7处(4%),干骺端9处(5%);髌骨0处.结论 MRI能很好地显示膝关节的骨缺血坏死改变.在使用糖皮质激素治疗的患者中,应尽早行MR检查,以便早期诊断和早期治疗。
Abstract 12137: Pivotal Role of the Left Anterior Descending Coronary Artery in Sudden Cardiac Arrest
Authors: Jason Tso, Sandeep Nair, Kyndaron Reinier, Sam Dawkins, Audrey Uy-Evanado, Carmen Rusinaru, Eric C Stecker, Saibal Kar, Jonathan Jui, Sumeet S Chugh
Journal: Circulation (2018)

Introduction: Sudden cardiac arrest (SCA) is often associated with coronary artery disease (CAD). However, the specific nature and patterns of coronary lesions and ischemia require more investigati...
Relationship of KIAA1199 on neutrophil recruitment and promotion of colorectal cancer liver metastasis via TGF-β signaling.
Authors: Haihong Wang, Zhenyu Lin, Tao Zhang, Jinghua Ren
Journal: Journal of Clinical Oncology (2020)

e16005 Background: Metastasis is the main cause of cancer-related death governed by both cancer cell-intrinsic properties and extrinsic immune contexture. Our previous reports have suggested critical roles of KIAA1199 in tumor invasion and metastasis in colorectal cancer (CRC). In the present study, we explored the potential effects of KIAA1199 on pre-metastatic niche formation. Methods: The CIBERSORT algorithm analysis for 241 patients with colorectal cancer from the Cancer Genome Atlas was performed to investigate the relationship between KIAA1199 expression and neutrophil accumulation. Neutrophils and T cells were isolated, stimulated and/or cultured for in vitro function assays. Proteins were knocked down in MC38 and HCT116 colorectal cancer cell lines, which were analyzed by immunoblotting and chemotaxis assays. Results: We demonstrate that patients with high KIAA1199 showed an increased level of liver-infıltrating neutrophils, which is further validated using flow cytometry analyses in mouse metastasis model. The increased influx of neutrophils is associated with KIAA1199-driven CRC liver metastasis. Neutrophils isolated from pre-metastatic niche decreased CD8+ T cells infiltration and IFN-r+ CD8+ T cells proportion in vivo. Moreover, they showed a N2-like phenotype and expressed higher level immunosuppressive molecules when exposed to the supernatant of normal CRC cell compared to KIAA1199-knock down cell. In CRC cells, we also found a positive correlation between expression of KIAA1199 and genes that ELR+ chemotaxis of neutrophil (CXCL1/CXCL3/CXCL5), which recruited neutrophils to CRC tumor via CXCR2. Importantly, LY2109761, a TGF-β receptor inhibitor, is sufficient to reduce the mRNA levels of these genes. Furthermore, there is a positive correlation between expression of KIAA1199 and expression of Transforming Growth Factor beta pathway genes (TGFBR1, TGFBR2, and pSMAD3), and further co-immunoprecipitation analysis suggests that KIAA1199 may activate the TGF-β signaling pathway via interacting with the TGFBR1 or TGFBR2. Conclusions: Our data indicate that the upregulation of KIAA1199 may increase the expression of cytokines mediated by TGF-β signaling, which can recruit metastasis-supporting neutrophils to promote colorectal cancer liver metastasis. Blockade of the TGF-β signaling could be a novel therapeutic approach against KIAA1199-high expression CRC.
Hyperurecemia and kidney disease
Authors: Yuqing Chen
Journal: BMJ (2017)

尿酸是人体内重要的小分子物质，是嘌呤代谢的终产物，目前对其功能和作用仍不完全清楚。人类的血尿酸水平高于绝大多数动物，是物种进化过程中分解尿酸的酶突变后失去功能造成的。因此肾脏是人类排出尿酸的主要器官，在尿酸的平衡中起重要作用。尿酸在肾脏的排泄过程复杂，经历滤过、重吸收和分泌的一系列过程。肾小管上皮细胞上有大量的尿酸转运子，多为协同转运子，因此尿酸的重吸收和分泌受多种物质的影响，此特点使尿酸可作为肾小管损伤的一种生物标志物。另一方面，高尿酸血症可引起痛风，在特定情况下可能成为脏器损伤的因素，如急性高尿酸血症和肾结石，而慢性高尿酸血症肾病的诊断仍存在争议。在发现高尿酸血症时，首先要仔细鉴别原因，合并痛风者需要药物控制尿酸水平在合理范围，对无症状的高尿酸血症是否行降尿酸药物治疗仍无定论。
Nutritional index and immune function in esophageal cancer patients with early enternal nutrition
Authors: Zhen-bing You, Da-fu Xu, Wei-guo Zhu, Jian Ji, Yong Xiao, Wei Guo
Journal: BMJ (2012)

One hundred and seventeen patients with esophageal squamous cell carcinoma were treated with radical esophagectomy from January 2011 to June 2011,among whom 63 cases received early enteral nutrition (study group) and 54 received parenteral nutrition (control group).There were no differences in serum levels of albumin (ALB),prealbumin (PAB) and transferrin (TRF) before surgery between two groups.Serum PAB and TRF levels in study group were significant higher than those in control at d8 after surgery(P ＜ 0.05),and also higher than those at d1 after surgery (P ＜ 0.05).There were no differences in immune indexes in two groups before surgery,the IgA and IgM levels were rising at d8 compared those at d1 after surgery.The total lymphocytes,CD3,CD4,CD8 and CD4/CD8 in study group at d8 were significant higher than those in control group and those at d1 after surgery.The study shows that early enteral nutrition can improve nutritional index and immune function,and to promote rapid rehabilitation in esophageal cancer patients after surgery.

Key words: 
Esophageal neoplasms; Enteral nutrition
逆行切除法在电视腹腔镜胆囊切除术中的应用优势
Authors: 魏力, 朱林, 唐荣生, 郭和, 冯静刚
Journal: BMJ (2008)

电视腹腔镜胆囊切除术(LC)是在我国开展最广泛、最成熟、例数最多的微创手术,目前已成为治疗胆囊结石公认的金标准.1992年10月至2006年12月我科共行LC治疗9826例,随着手术例数的增多积累了一定的经验,也发现了一些需要注意和改进的地方,特别是对LC中胆囊三角(Calot三角)的多种变异,胆囊及周围不同的病理改变、结石大小与部位各异等多种特殊情况,术中无法辨认和分离胆囊管及胆囊动脉,误扎、损伤肝外胆管等情况的处理。
下腔静脉滤器对肺栓塞的预防作用观察
Authors: 付强, 王临光, 黄宜杰, 吴强, 王彦炯, 王海波, 蒋树中, 张毅刚, 路雯
Journal: BMJ (2008)

深静脉血栓形成(deep venous thrombosis,DVT)是急性肺栓塞(acute pulmonary embolism,APE)最常见的原因[1-2].置入下腔静脉滤器(inferior vena cava filter,IVCF)是预防DVT患者反复发生肺栓塞的有效手段[3-4]。
Characterizing the molecular and immunological features of lung micropapillary adenocarcinoma.
Authors: Shirong Zhang, Yang Xu, Pan Zhao, Hua Bao, Xiyong Wang, Rui Liu, Rujun Xu, Jingjing Xiang, Hong Jiang, Junrong Yan, Xue Wu, Yang Shao, Jiafeng Liang, Qiong Wu, Zhihao Zhang, Shun Lu, Shenglin Ma
Journal: Journal of Clinical Oncology (2020)

e21036 Background: Micropapillary adenocarcinoma (MPC) is one of the most aggressive histologic subtypes of lung adenocarcinoma (ADC). Although the incidence of MPC predominant ADC is low, nearly half of ADCs contain a minor proportion of MPC, which could contribute to poor prognosis in these patients. Comprehensive analysis of genetic and immunological features of ADC with different MPC contents would help better understand cancer biology of this ADC subtype and direct future treatments. Methods: We performed panel next-generation sequencing (NGS) of 425 cancer-related genes for a discovery cohort of 43 ADC patients whose tumors were microdissected to separate MPC and non-MPC regions and a reference cohort of 113 ADC patients with unknown ADC histologic subtypes. MPC-enriched mutations were identified by comparing tumors with different original MPC contents within these cohorts, which was then confirmed using a validation cohort of 183 ADC patients. Staining of immunological markers was also conducted for MPC samples from the discovery cohort to investigate their tumor microenvironment. Results: We found that ADC tumors with higher MPC contents/similarities tended to harbor more tumor mutation burdens (TMBs) and chromosome instability (CIN). In addition, genetic alterations in transcription termination factor 1 ( TTF1), brain-specific angiogenesis inhibitor 3 ( BAI3), mammalian target of rapamycin ( MTOR), cyclin-dependent kinase inhibitor 2A ( CDKN2A), and CDKN2A were found to be enriched in MPC using the discovery and reference cohorts, which could then be cross-validated using the validation cohort. Tumors with higher MPC content were associated with elevated infiltration of CD4+, CD8+ and FOXP3+ T cells, especially at the peritumor regions. Higher percentage of PD-L1+ tumor cells were also found to be correlated with higher MPC content, suggesting of more immunosuppression in MPC predominant tumors than low MPC tumors. Conclusions: We identified multiple novel MPC-enriched genetic changes that could help understand the nature of MPC. MPC predominant tumors tended to have higher levels of TMBs, T cell infiltration, and immunosuppression than low MPC tumors, making it a potential candidate for immunotherapy, especially the combination therapy of anti-PD-1/PD-L1 drugs and anti-CTLA-4 drugs, which could inhibit PD-1/PD-L1 pathway and FOXP3+ T reg cells simultaneously.
Anlotinib in patients with recurrent advanced cervical cancer: A prospective single-arm, open-label, phase Ⅱ trial.
Authors: Xiaohua Wu, Jun Zhu
Journal: Journal of Clinical Oncology (2020)

6034 Background: Anlotinib is a novel multi-target tyrosine kinase inhibitor that has previously shown clinical antitumor activity in various cancers, including the phase I study on female genital tumors. This phase II study (ChiCTR1800020116) aims to further evaluate the safety and efficacy of anlotinib, in those patients with recurrent advanced cervical cancer. Methods: Eligible patients were advanced cervical cancer who had received at least two previous lines of chemotherapy. Patients were given anlotinib (12 mg/day) from day 1 to day 14 in a 21-day cycle until disease progression or had unacceptable toxic effects. The primary endpoint of this study was objective response rate (ORR) and the secondary endpoints were progression-free survival (PFS), overall survival (OS) and safety. Results: Between 2018 December and 2019 October, 41 patients (female) were enrolled. As of January 15, 2020, median follow-up duration, from randomization to data cutoff, was 2.6 months (range, 0.7-10.3). Therapeutic evaluation showed the ORR was 32.1% (95%CI, 13.7%-50.6%) and the median PFS was 3.9 months (95% CI, 1.3%-6.5%). The most frequently reported adverse events were lymphocyte count decreased, anemia, hand-foot syndrome, blood uric acid increased, blood creatinine increased, blood thyroid stimulating hormone increased. All frequently occurring AEs were grade 1 or 2. High grade AE was only observed in 1 patient with white blood cells urine positive of grade 3. Neither unexpected safety signals nor treatment related death occurred. Conclusions: Anlotinib showed a promising activity with an acceptable safety profile for patients with recurrent advanced cervical cancer. Clinical trial information: ChiCTR1800020116.
Survival of head and neck rhabdomyosarcoma in children: a clinical analysis of 98 cases
Authors: Yi Zhang, Weiling Zhang, Dongsheng Huang, Yizhuo Wang, You Yi, Song Li
Journal: BMJ (2019)

Objective
To analysis the prognosis of head and neck rhabdomyosarcoma (RMS) in pediatrics.


Methods
The clinical data of 98 pediatric patients with head and neck RMS admitted from February 2005 to September 2017 were retrospectively analyzed. The clinical staging and risk grouping were performed according to international rhabdomyosarcoma study group criterion. The treatment included chemotherapy, radiotherapy and surgery accordingly. The association of prognosis with the disease characters, treatment strategy of 98 patients RMS was analyzed by Chi-square test and Kaplan-Merier analysis with SPSS 20.0 software.


Results
There were 53 boys (54.1%) and 45 girls (45.9%) with a median age of 70 months (2-161 months). There were 43 cases of orbit RMS (43.9%) , 46 cases of paramenigneal RMS (46.9%) and 9 cases of non-paramenigneal and non-orbit RMS (9.2%) . Twenty seven patients were classified as low risk (27.6%), 42 patients as medium risk (42.9%), and 29 patients as high risk (29.5%). The patients were followed up for a medium of 42 months (9-149 months), 37 cases were dead, 60 cases were survival, and 1 lost the follow-up. Kaplan-Merier survival analysis showed that the overall survival (OS) was 61.9% (60/97), and the average survival time was (92.3±6.9) months. Univariate analysis showed that the OS of patients with paramenigneal RMS was poorer than that of patients with orbit RMS, non-paramenigneal and non-orbit RMS. The OS of high risk RMS patients was poorer than that of intermediate and low risk patients (χ2=6.132, P=0.047) .


Conclusions
The prognosis of head and neck RMS in children is generally good, but the prognosis of paramenigneal RMS and high-risk RMS is significantly declined. The primary site of paramenigneal and high risk are independent risk factors for the prognosis of head and neck RMS in children.


Key words: 
Rhabdomyosarcoma; Child; Head and neck neoplasms; Prognosis
Impact of neoadjuvant chemotherapy on surgery and prognosis in patients with stage III gastric cancer
Authors: Wang Jun, Song Zhan, Dou Yanyan, Lyu Ke, Zhao Yuting, Zhang Haiyang
Journal: BMJ (2016)

Objective
To investigate the impact of neoadjuvant chemotherapy on surgery and prognosis in patients with stage Ⅲ gastric cancer.


Methods
The 90 cases staging Ⅲ gastric cancer were randomly divided into neoadjuvant chemotherapy group and surgery group. Both surgical complications and prognosis were compared.


Results
The overall effective rate of neoadjuvant chemotherapy was 53%(24/45), disease control rate of neoadjuvant chemotherapy was 91%(41/45). Blood loss(t=4.102, P=0.037), local adhesions surgery(χ2=19.756, P=0.000), local tissue necrosis(χ2=13.512, P=0.000), tissue fragility (χ2=12.870, P=0.000)number of cases found in neoadjuvant chemotherapy group were higher than surgery group, and the data were statistically significant.There were no statistically significance between two groups about operation time(t=2.391, P=0.129), tissue congestion(χ2=0.865, P=0.352), postoperative bleeding(χ2=0.720, P=0.396), postoperative fistula(χ2=1.047, P=0.306). The survival time of neoadjuvant chemotherapy group was longer than surgery group, but it was not statistically significant(t=1.086, P=0.372).


Conclusions
Neoadjuvant chemotherapy could reduce the stage of the gastric cancer and increase the complexity of surgery. Thus preoperative evaluation should be prepared before the surgery.


Key words: 
Stomach neoplasms; Chemotherapy, adjuvant; Surgical procedures, operative; Prognosis
Prevalence of lower urinary tract symptoms in young and adolescent females in Luoyang City
Authors: 周志强, 郭素珍, 俞维, 张翠兰, 杜广辉, 夏晓燕
Journal: BMJ (2007)

目的 调查分析洛阳市青少年女性尿急、尿频、遗尿、尿失禁等下尿路症状的发生情况.方法 在洛阳市某初中、高中、大学在校女生采取整层随机抽样,抽取1800人,采用女性尿失禁症状调查问卷,由被调查对象自己填写无记名式调查问卷.结果 发出问卷1800份,回收有效问卷1739份.被调查人群中尿频发生率6.04%,其中初中、高中、大学组发生率分别为1.20%、9.38%、7.60%,3组比较差异有统计学意义(P＜0.01).尿急发生率51.2%,3组发生率分别为53.43%、50.62%、49.66%;遗尿发生率1.50%,3组发生率分别为2.41%、0.71%、1.35%;尿急和遗尿3组间比较差异均无统计学意义(P＞0.05).初中、高中、大学组尿失禁患病率分别为20.45%、10.44%、16.72%,3组比较差异有统计学意义(P＜0.01);尿失禁总患病率为15.93%,其中压力性尿失禁、急迫性尿失禁、混合性尿失禁分别为10.18%、1.67%、4.08%,其构成比为63.90%、10.47%、25.63%,差异无统计学意义(P＞0.05).结论 青少年女性下尿路症状发生率较高,应引起妇产科和泌尿外科医生的高度重视,加强有关下尿路症状方面的卫生宣教和治疗工作,以减轻和延缓尿失禁症状的发生。
A phase II study of selective HDAC6 inhibition with KA2507 for second-line treatment of advanced biliary tract cancer (ABC-11).
Authors: John A. Bridgewater, Philip Beer, Jennifer Bendall, Hakim-Moulay Dehbi, Marian Duggan, Michelle Hung, Justine King, Hilary McElwaine-Johnn, Laura White
Journal: Journal of Clinical Oncology (2020)

TPS4652 Background: The ABC-02 trial provided Level A evidence supporting the use of cisplatin plus gemcitabine as first-line chemotherapy for advanced biliary tract cancer (ABC) [Valle, 2010]. In second line therapy oxaliplatin and 5FU and ivosedinib for IDH1 mutated cancers are options [Lamarca, 2019; Abou-Alfa, 2019] however there remains significant unmet need for patients without actionable alterations. Histone deacetylase 6 (HDAC6) is over-expressed in cholangiocarcinoma, reducing primary cilia. This is mediated through increased resorption in normal human cholangiocytes via tubulin deacetylation in the ciliary axoneme. Inhibition of HDAC6 elicits both cell intrinsic and extrinsic anti-cancer activity. HDAC6 inhibition reversed oncogenic loss of ciliation and demonstrated preclinical efficacy in a syngeneic rat orthotopic biliary cancer model [Gradilone, 2013]. KA2507 is a potent and selective small molecule inhibitor of HDAC6. Phase I dose escalation study identified an oral dose of 800mg bid for further development, being well tolerated and showing evidence of selective target engagement. Methods: ABC-11 is a Phase II multi-centre, open-label study of KA2507 in 40 evaluable patients with advanced biliary tract cancer previously treated with standard of care chemotherapy. The study follows a single-arm single-stage design using A’Hern’s methodology. Eligible patients receive continuous 28-day cycles of fixed daily oral dose of KA2507 until death, disease progression or other pre-defined reason for study drug discontinuation. Tumour assessment is made at baseline and at 8-weekly intervals using RECIST 1.1 criteria until disease progression; primary endpoint is PFS at 4 months. Independent Data Monitoring Committee will review 4 month PFS and other data after first six patients, after a total of 17 patients (futility analysis, corresponding to cut-off of the Simon’s minimax 2-stage design; 33% was set as the target 4-month PFS rate expected with KA2507) and at least annually thereafter. Subject to availability of adequate tissue, mandatory pre-treatment and on-study tumour biopsy samples will undergo multiparameter flow cytometry of immune cell subsets, immunofluorescence analysis of immune cell subsets (activation status and topology) and T cell repertoire studies. The study received regulatory and ethical approval to proceed in January 2020 and enrolment is in progress. Clinical trial information: NCT04186156 .
Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators
Authors: A. Bardia, C. Loprinzi, A. Grothey, G. Nelson, S. Alberts, S. Patiyil, S. Thome, S. Gill, D. Sargent
Journal: Journal of Clinical Oncology (2009)

e15031 Background: Two web based prognostic calculators, Adjuvant! and Numeracy (JCO 22:1797–1806, 2004) are widely used to provide individual patient outcome predictions to aid decisions regarding adjuvant therapy for colon cancer. The comparability of these tools has not been studied yet. The aim of this project was to assess whether the Numeracy and Adjuvant! Colon cancer prognostic tools produced similar results for patients with resected stage II and III colon cancer based on a set of hypothetical patients. Methods: All possible hypothetical scenarios were formulated for the Numeracy calculator based on all potential combinations of age, lymph nodes status, tumor stage, and grade of tumor. These were applied to three post- surgical therapy choices: observation, 5-FU (5-fluorouracil), or FOLFOX (5-FU, leucovorin and oxaliplatin). Predictions for these hypothetical scenarios (N= 192 for males and 192 for females) were also entered into the Adjuvant! Program. Predicted relapse free survival (RFS) and overall survival (OS) were obtained using both calculators. Wilcoxon signed rank tests were used to compare the numerical predictions between the calculators for each outcome. Results: In the majority of the 384 hypothetical patient scenarios, predictions for RFS and OS from Adjuvant! were statistically significantly higher than from Numeracy (p value &lt; 0.05), except for age≥70 for FOLFOX, and the number of positive nodes of 0 and 1–4 using FOLFOX, among males. The net estimate of benefit for RFS and OS for 5-FU over surgery, obtained from Adjuvant! and Numeracy, were similar (for both males and females), but the benefit in RFS and OS for FOLFOX over 5-FU obtained from Adjuvant! was significantly lower than the estimate obtained from Numeracy (p value &lt; 0.05). Conclusions: Based on a hypothetical set of patients with resected stage II and III colon cancer, the estimated benefit in RFS and OS of FOLFOX over 5-FU based chemotherapy is lower in Adjuvant! than in the Numeracy tool (but benefit for 5-FU over surgery alone is similar). Further studies are needed to clarify the discrepancy and to assess which of these tools most accurately reflects actual patient outcome. No significant financial relationships to disclose.
Interpretation of management of massive and submassive pulmonary embolism: a scientific statement from the American Heart Association
Authors: Zhen-nan Li, Chang-ming Xiong
Journal: BMJ (2012)

急性肺栓塞是一种高发病率和高死亡率的心血管急症，及时的诊断和规范的治疗可以降低其死亡率，改善预后。2011年美国心脏协会发表了大面积肺栓塞和次大面积肺栓塞、髂股深静脉血栓形成以及慢性血栓栓塞性肺动脉高压的处理的科学声明。本文针对其中有关急性肺栓塞诊断和治疗策略部分进行解读，以尽快让我国临床医生了解该声明的主要内容，进一步提高急性肺栓塞诊治水平。